PDF Cover

Pulmonary Artery Stent System Market

The market for Pulmonary Artery Stent System was estimated at $234 million in 2025; it is anticipated to increase to $310 million by 2030, with projections indicating growth to around $412 million by 2035.

Report ID:DS1801188
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Pulmonary Artery Stent System
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Pulmonary Artery Stent System Market Outlook

Revenue, 2025

$234M

Forecast, 2035

$411M

CAGR, 2026 - 2035

5.8%

The Pulmonary Artery Stent System industry revenue is expected to be around $247.8 million in 2026 and expected to showcase growth with 5.8% CAGR between 2026 and 2035. This steady market expansion reflects the growing clinical importance of minimally invasive cardiovascular interventions and the increasing need for effective treatment of pulmonary artery stenosis in both pediatric and adult patients. Rising prevalence of congenital heart defects, post-surgical vascular complications, and structural heart disorders is strengthening demand for advanced stent-based treatment solutions. Hospitals and cardiac centers are prioritizing interventional procedures that reduce recovery time, improve patient outcomes, and lower surgical risks compared to open-heart operations. Continuous advancements in catheter-based technologies, imaging guidance, and biocompatible stent materials are further supporting wider adoption and long-term market relevance across specialized cardiovascular care.

Pulmonary artery stent systems are specialized medical devices designed to restore and maintain blood flow in narrowed or obstructed pulmonary arteries by providing structural support through minimally invasive catheter-based placement. These systems typically include balloon-expandable or self-expanding stents made from high-strength biocompatible materials such as cobalt-chromium or stainless steel, ensuring durability and long-term vessel patency. Their major applications include the treatment of congenital pulmonary artery stenosis, postoperative vascular narrowing, and complex cardiovascular conditions requiring targeted vessel reconstruction. Pediatric cardiology remains a major application area, while adult structural heart interventions are also expanding. Recent market trends include increasing preference for image-guided interventional cardiology, development of flexible low-profile stent designs, and growing use of customized stent solutions for complex anatomies, all of which are driving sustained global demand.

Pulmonary Artery Stent System market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Pulmonary Artery Stent System Market Outlook

Market Key Insights

  • The Pulmonary Artery Stent System market is projected to grow from $234.2 million in 2025 to $412 million in 2035. This represents a CAGR of 5.8%, reflecting rising demand across Chronic Thromboembolic Pulmonary Hypertension Management, Treatment of Pulmonary Artery Stenosis, and Pulmonary Arteriovenous Malformation Procedure.

  • The market exhibits an oligopolistic structure with only 7 prominent players, with NuMED Inc. and Cordis commanding the largest shares.

  • U.S. and Germany are the top markets within the Pulmonary Artery Stent System market and are expected to observe the growth CAGR of 3.8% to 5.6% between 2025 and 2030.

  • Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 6.7% to 8.0%.

  • End-User Companies within Pulmonary Artery Stenosis are adopting transition like Transition from Surgical Correction to Minimally Invasive Stent-Based Interventions; and this trend is expected to give an additional push of $11 million to Pulmonary Artery Stent System industry b/w 2025 and 2030.

  • The Pulmonary Artery Stent System market is set to add $177 million between 2025 and 2035, with manufacturer targeting Post-surgical PAO & Off-label Use Application projected to gain a larger market share.

  • With

    the increasing prevalence of pulmonary artery diseases, and

    Technological Advancements, Pulmonary Artery Stent System market to expand 76% between 2025 and 2035.

pulmonary artery stent system market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Pulmonary Artery Stent System - Country Share Analysis

Opportunities in the Pulmonary Artery Stent System

Chronic thromboembolic pulmonary hypertension management offers strong growth opportunities as hospitals increasingly adopt catheter-based pulmonary interventions. Balloon-expandable pulmonary artery stents are also expected to grow most because they provide strong radial support and accurate placement in narrowed vessels after thromboembolic obstruction. Specialized cardiac centers are combining balloon pulmonary angioplasty with stent placement for complex lesions to improve long-term vascular patency and reduce repeat procedures. North America and Europe lead current adoption, while advanced tertiary hospitals in Asia are emerging as important future demand centers for these interventions.

Growth Opportunities in North America and Asia-Pacific

North America is a player in the global medical field and holds promising opportunities for products like the Pulmonary Artery Stent System due to continuous technological progress and strong healthcare infrastructure in the region. The rising prevalence of diseases and an aging population susceptible to pulmonary issues make it crucial to embrace effective treatments like the Pulmonary Artery Stent Systems. The market competition is robust with renowned companies such as Medtronic and Abbott Laboratories playing a role, in shaping regional developments and progressing the system further. In North America the primary drivers of the market are the ability to spend in healthcare and the existence of medical device manufacturers.
The Asia Pacific region is experiencing growth in the market for Pulmonary Artery Stent Systems due to increasing cases of cardiovascular diseases and the demand for less invasive treatments in countries such as China, India and Japan. Health awareness and government efforts to improve healthcare standards are driving the adoption of medical devices, in this region. Both established companies and new entrants are vying for market share in a landscape that is fuelin g its growth. The thriving medical tourism sector in the Asia Pacific region is being fueled by factors such as a growing population and increased accessibility to treatments, like the Pulmonary Artery Stent System.

Market Dynamics and Supply Chain

01

Driver: Rising Congenital Heart Disease Cases and Growth of Pediatric Interventions

The increasing prevalence of congenital heart defects is also a major driver for the pulmonary artery stent system market, particularly in pediatric cardiology. Many children born with pulmonary artery stenosis require early interventional treatment to restore normal blood flow and reduce long-term cardiac complications. This has also significantly increased demand for balloon-expandable stent systems that allow precise placement and future redilation as the child grows. At the same time, the expansion of pediatric interventional cardiology centers and specialized cardiac hospitals is also strengthening market growth. Improved catheter-based treatment protocols and earlier diagnosis through advanced imaging are also helping physicians adopt minimally invasive stent procedures more frequently, supporting stronger procedural volumes and long-term market demand.
Continuous innovation in low-profile and highly flexible stent designs is also accelerating adoption across complex cardiovascular procedures. Modern pulmonary artery stent systems are also being developed with improved deliverability, stronger radial force, and better compatibility with small or tortuous vessel anatomy. These advancements are also especially valuable in pediatric and high-risk adult cases where procedural precision is also critical. Enhanced catheter navigation and image-guided deployment reduce procedural complications and improve physician confidence. As hospitals prioritize minimally invasive structural heart interventions, demand for advanced pulmonary artery stent platforms continues to rise, strengthening commercial opportunities for manufacturers across specialized cardiovascular care markets.
02

Restraint: High Procedure Costs and Limited Reimbursement Reduce Treatment Accessibility

Pulmonary artery stent system procedures require specialized stents, advanced imaging support, catheter-based intervention facilities, and highly trained cardiac specialists, making overall treatment costs significantly high. In many developing healthcare systems, reimbursement coverage for newer stent technologies remains limited, forcing hospitals and patients to delay or avoid treatment decisions. Pediatric-specific and customized stent systems are particularly expensive, further restricting adoption in congenital heart disease cases. This directly affects procedural volumes and market revenue, as providers often choose lower-cost alternatives such as repeated balloon angioplasty or surgical correction instead of advanced stent implantation.
03

Opportunity: Customized Covered Stents Support Complex Pulmonary Malformation Procedures and Pediatric Cardiology Expansion in Asia Creates Strong Stent Demand

Pulmonary arteriovenous malformation treatment creates a niche opportunity for covered pulmonary artery stent systems in tertiary care hospitals. Covered stents are expected to grow steadily because they help isolate abnormal vessel connections while preserving healthy pulmonary circulation in complex anatomies. Manufacturers are increasingly focusing on low-profile and customized stent platforms to improve deployment precision and physician confidence during interventional radiology procedures. Strategic collaboration between cardiovascular device companies and specialty hospitals is accelerating adoption, particularly in high-value structural heart and rare vascular disease treatment segments across developed healthcare markets. 
The growing pediatric cardiology sector in Asia Pacific creates major opportunities for pulmonary artery stent systems, especially for congenital pulmonary artery stenosis treatment. Balloon-expandable stents are expected to witness the strongest growth because they allow precise sizing and future redilation in children. Countries such as China and India are expanding pediatric interventional cardiology infrastructure, supported by rising congenital heart disease diagnosis and improved minimally invasive treatment access. Asia Pacific is projected as the fastest-growing regional market for pediatric interventional cardiology, strengthening long-term demand for specialized pulmonary artery stent procedures.
04

Challenge: Strict Regulatory Requirements and Limited Specialist Availability Slow Market Expansion

Pulmonary artery stent systems face strict regulatory approval requirements because long-term safety, vessel compatibility, and procedural outcomes must be clearly demonstrated before commercial approval. Extended clinical validation increases development costs and delays product launches, especially for smaller manufacturers with limited resources. At the same time, these procedures require experienced pediatric and structural heart interventionalists, which limits adoption in smaller hospitals and emerging markets. For example, facilities without specialized cardiac teams may refer patients for surgery instead of stent placement, reducing demand growth and slowing competitive market expansion across underserved regions.

Supply Chain Landscape

1

Raw Material Supply

ATI Specialty Alloys & ComponentsCarpenter TechnologyFort Wayne Metals
2

Component & Catheter Manufacturing

Teleflex Medical OEMFreudenberg MedicalTube Methods
3

Stent System Manufacturing

NuMED Inc.CordisRenata Medical
4

Hospitals & Applications

Pediatric Cardiology CentersInterventional Cardiology HospitalsPulmonary Artery Stenosis Treatment
Pulmonary Artery Stent System - Supply Chain

Use Cases of Pulmonary Artery Stent System in Chronic Thromboembolic Hypertension Management & Treatment of Stenosis

Chronic Thromboembolic Pulmonary Hypertension Management : In chronic thromboembolic pulmonary hypertension management, balloon-expandable pulmonary artery stent systems are commonly used to restore blood flow in narrowed pulmonary vessels following thromboembolic obstruction. These stents are preferred in specialized cardiac hospitals and interventional cardiology centers because they provide precise placement and strong radial support in affected arteries. They are often used alongside balloon pulmonary angioplasty to improve vascular patency and reduce right heart strain. Their controlled expansion helps physicians manage complex lesions with better procedural accuracy, improving oxygen circulation and supporting long-term symptom relief for patients with advanced pulmonary vascular disease.
Treatment of Pulmonary Artery Stenosis : In the treatment of pulmonary artery stenosis, both balloon-expandable and self-expanding stent systems are widely used depending on vessel anatomy and patient age. Pediatric cardiology centers frequently prefer balloon-expandable stents for congenital pulmonary artery narrowing because they allow accurate sizing and future redilation as the child grows. In adult patients, self-expanding stents are also used for flexible adaptation in complex vascular structures. These systems help restore normal blood flow, reduce pressure overload on the heart, and minimize the need for repeat surgeries. Their minimally invasive nature makes them highly valuable in long-term cardiovascular management.
Pulmonary Arteriovenous Malformation Procedure : For pulmonary arteriovenous malformation procedures, covered stent systems and selective vascular stents are commonly applied to isolate abnormal vessel connections while preserving healthy pulmonary circulation. Interventional radiology units and tertiary care hospitals use these stents in patients with complex vascular malformations where embolization alone may not provide sufficient structural support. Covered stents are especially useful in preventing abnormal blood shunting between arteries and veins, reducing risks of hypoxemia and neurological complications. Their targeted deployment improves procedural safety and helps maintain stable long-term pulmonary function in patients with rare but clinically significant vascular abnormalities.

Impact of Industry Transitions on the Pulmonary Artery Stent System Market

As a core segment of the Medical Device industry, the Pulmonary Artery Stent System market develops in line with broader industry shifts. Over recent years, transitions such as Transition from Surgical Correction to Minimally Invasive Stent-Based Interventions and Shift from Standard Vascular Devices to Customized Pulmonary Stent Solutions have redefined priorities across the Medical Device sector, influencing how the Pulmonary Artery Stent System market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Transition from Surgical Correction to Minimally Invasive Stent-Based Interventions

The pulmonary artery stent system market is shifting from traditional open surgical correction toward minimally invasive catheter-based stent procedures, especially in congenital heart disease and pulmonary artery stenosis treatment. Hospitals and cardiac centers increasingly prefer stent implantation because it reduces recovery time, lowers surgical risk, and improves long-term patient management. For example, pediatric cardiology centers are replacing repeat surgical corrections with balloon-expandable stent procedures that allow future redilation as children grow. This transition is increasing demand for advanced interventional cardiology equipment and strengthening revenue opportunities for cardiovascular device manufacturers and specialized cardiac care providers.
02

Shift from Standard Vascular Devices to Customized Pulmonary Stent Solutions

The industry is moving from the use of general vascular stents toward specialized pulmonary artery stent systems designed for complex anatomy and structural heart conditions. Manufacturers are focusing on low-profile, flexible, and covered stent designs that improve procedural precision in pulmonary artery stenosis and pulmonary arteriovenous malformation procedures. For example, tertiary care hospitals increasingly demand customized covered stents for rare vascular malformations where standard peripheral stents are less effective. This transition is driving innovation across medical device development, increasing strategic partnerships between hospitals and device companies, and creating stronger differentiation within the structural heart intervention market.